Reuters logo
BRIEF-Kyowa Hakko Kirin Announces FDA Acceptance For Filing And Priority Review Designation Of Mogamulizumab's Biologics License Application
November 28, 2017 / 12:57 PM / in 14 days

BRIEF-Kyowa Hakko Kirin Announces FDA Acceptance For Filing And Priority Review Designation Of Mogamulizumab's Biologics License Application

Nov 28 (Reuters) - Kyowa Hakko Kirin Co Ltd:

* KYOWA HAKKO KIRIN ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW DESIGNATION OF MOGAMULIZUMAB‘S BIOLOGICS LICENSE APPLICATION Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below